The news broke a few hours ago: the health authorities now have the Johnson & Johnson vaccine in their sights. Indeed, many American patients suffering from COVID-19, who received the first doses of the J&J vaccine, have been detected with cases of thrombosis (blood clots).
Discover our latest podcast
It is the FDA that is 'investigating six reported cases in the United States of people developing severe blood clots after receiving the vaccine.'
While waiting for the results, the American health authorities took the decision to temporarily stop vaccinations as of Tuesday 13 April:
We are recommending a pause in the use of this vaccine out of an abundance of caution.
And yet, the link with thrombosis was denied
Just a few days ago, the newspaper Capital revealed in an article that no link between the J&J vaccines and thrombosis had been found. And yet, it was the FDA that warned the media:
At the moment, we have not found a causal link with vaccination and we are continuing our investigation and evaluation of these cases. We will keep the public informed as we learn more.
We are still waiting for the results of the studies actively carried out by the scientists.
Johnson & Johnson vaccine delayed for the UK
With an 85% efficiency and a single dose administration, the Johnson & Johnson vaccine seems like a straight improvement over its competitors. And yet this US decision is going to delay the European and English rollout. Johnson & Johnson announced that they would carry out even more testing.
It's expected that, as with the AstraZeneca vaccine, younger people will be advised to seek other vaccination options for their jab.
